First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR in Patients with BRAF V600E-mutated mCRC By Ogkologos - February 17, 2025 762 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Lazertinib December 4, 2024 Staging at Presentation for Patients with Localised Pancreatic Ductal Adenocarcinoma Should... February 8, 2024 Hormone Therapy Has A Stronger Impact On A Woman’s Quality Of... October 16, 2019 ΚΑΡΚΙΝΟΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ March 8, 2019 Load more HOT NEWS From Practice-Changing Data to Future Innovation, Patient Outcomes to Doctors’ Wellbeing,... HER2 Expression is a Determinant of Sensitivity to Trastuzumab Deruxtecan in... FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid... Active Surveillance for Low-Risk Prostate Cancer Continues to Rise
